Lurbinectedin is a relatively new drug that was approved by the FDA in 2020 for the treatment of metastatic small cell lung cancer (SCLC) [3]. According to DrugPatentWatch, as of 2021, there are no generic versions of Lurbinectedin available, and the drug is still under patent protection [1]. As a result, the cost of Lurbinectedin is relatively high compared to other similar drugs.

Drugs.com compares Lurbinectedin to another drug called Topotecan, which is also used to treat SCLC. According to the website, the cost of Lurbinectedin is significantly higher than Topotecan. The average retail price for a 4 mg vial of Lurbinectedin is around $4,400, while the average retail price for a 4 mg vial of Topotecan is around $500 [2].

However, it's important to note that the cost of Lurbinectedin may vary depending on a variety of factors, including insurance coverage, dosage, and treatment duration. Additionally, Lurbinectedin is a newer drug with a different mechanism of action than Topotecan, and it may be more effective for some patients.

In summary, Lurbinectedin is a relatively expensive drug compared to other similar drugs used to treat SCLC. However, the cost may be justified by its effectiveness and unique mechanism of action. Patients should consult with their healthcare provider and insurance company to determine the best treatment option for their individual needs and budget.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.drugs.com/compare/lurbinectedin
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/